Seer Q3 2021 revenue $2.2M, net loss $18.4M; on track for broad release in early 2022

Seer, Inc.

2021-Q3 EPS reported -$0.85 revenue$3,551,000

Revenue $2.2M vs $72K in Q3 2020; product-related revenue $1.6M including $787K from related party.
Gross margin 54%; operating expenses $19.6M (up from $8.5M) due to higher compensation and public company costs.
Net loss $18.4M vs $8.2M; cash and investments $506.6M as of Sept 30, 2021.
Added new Limited Release customers; on track for high single-digit total; broad release expected early 2022.
Customer studies: Oregon Health (prostate cancer, 500-1000 samples), Broad Institute (proteome depth), Sanford Burnham (TMT), Protein Metrics (glycoproteome).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.